Antelope Dx to get series B financing round of €9 million from Whitefund and existing investors.

Antelope Dx, a Gent, Belgium-based manufacturer of a consumer point-of-need diagnostic platform for on-the-spot access to key health parameters., announced that it completed a €9 million ($10.7M) series B investment round.

The money was subscribed in a 50/50 ratio by an investment consortium led by Whitefund, and the existing A-round investors, and will enable Antelope to initiate clinical development of the urine-based self-test for sexually transmitted diseases Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG) towards an IVD product.

Antelope Dx, founded in 2019 as a spinoff from the Belgian biotech company MyCartis and led by CEO Hilde Windels, produces a device that is an urine-based test for Chlamydia trachomatis and Neisseria gonorrhea. The team is also developing tests for respiratory Influenza A/B and Sars-CoV-2, which people can do at home using a single swab sample.